3 weeks ago
14
Adria Cimino, The Motley Fool
Sun, July 19, 2026 astatine 5:30 PM CDT 5 min read
Johnson & Johnson (NYSE: JNJ) has been a top-performing banal this year. Investors, successful galore cases rotating retired of riskier assets, person looked for companies with a beardown way grounds of net growth, coagulated competitory positions, and a gross watercourse they tin number connected -- and J&J fits the bill.
As a healthcare player, J&J sells pharmaceuticals and aesculapian devices that guarantee a definite level of revenue, arsenic patients request their procedures nary substance what absorption the banal marketplace takes. Over time, the company's in-house probe and acquisitions person built a market-leading portfolio that has kept net climbing. Investors, acrophobic astir geopolitical uncertainties and risks to the artificial quality (AI) maturation story, turned to J&J successful the archetypal half, sending the banal to a 22% gain.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
Last week, J&J delivered a blowout net study and accrued full-year forecasts. But is it excessively precocious to bargain this healthcare giant? Let's find out.
A household sanction
You mightiness cognize J&J champion for user products that you regularly use, from Band-Aid marque bandages to Tylenol. They've made J&J a household name. But the institution really spun disconnected its user wellness business, which includes these products, arsenic Kenvue a fewer years ago. This was successful an effort to boost growth, with the thought of dedicating each of its resources to the higher-growth areas of pharmaceuticals and medtech.
The Kenvue spinoff came astatine a cardinal moment, arsenic J&J prepared to suffer exclusivity of its blockbuster immunology cause Stelara. At its highest successful 2024, Stelara brought successful much than $10 billion. But the impending introduction of rivals meant that Stelara income would driblet drastically.
J&J's determination was a omniscient one, and the latest 4th illustrates this. Solid show from immunology cause Tremfya and starring aggregate myeloma cause Darzalex compensated for Stelara declines and drove much than 6% maturation to $25 cardinal successful full gross -- keeping J&J connected way to scope its extremity of $100 cardinal successful yearly revenue. Darzalex gross jumped 18% to much than $4.2 cardinal successful the quarter, portion Tremfya soared 72% to $2 billion.
A caller headwind
J&J faced 1 headwind successful peculiar successful the quarter. The medtech part saw immoderate weakness -- successful an interrogation with CNBC, main fiscal serviceman Joseph Wolk said income of Abiomed bosom pumps slipped aft the merchandise of a survey questioning the usage of Impella pumps during immoderate high-risk procedures. Wolk said J&J plans to merchandise information successful the archetypal fractional of adjacent twelvemonth that should alleviate concerns. It's important to retrieve that the institution has 28 products oregon platforms that bring successful gross of astatine slightest $1 billion, offering it the substance needed for ongoing growth.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·